These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37933875)

  • 1. Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India.
    Seth T; Garg K; Mandal PK; Datta A; Verma S; Hanagavadi S; Thota UR
    Hematology; 2023 Dec; 28(1):2277497. PubMed ID: 37933875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy.
    Coppola A; D'Ausilio A; Aiello A; Amoresano S; Toumi M; Mathew P; Tagliaferri A;
    Haemophilia; 2017 May; 23(3):422-429. PubMed ID: 28181369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.
    Olasupo OO; Lowe MS; Krishan A; Collins P; Iorio A; Matino D
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014201. PubMed ID: 34407214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India.
    Seth T; John MJ; Chakrabarti P; Shanmukhaiah C; Verma SP; Radhakrishnan N; Dolai TK
    Haemophilia; 2024 Mar; 30(2):426-436. PubMed ID: 38147060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China.
    Liu G; Xin Q; Chen Z; Li L; Chen T; Wu R
    Clin Ther; 2021 Sep; 43(9):1536-1546. PubMed ID: 34392959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA.
    Castro Jaramillo HE; Moreno Viscaya M; Mejia AE
    Int J Technol Assess Health Care; 2016 Jan; 32(5):337-347. PubMed ID: 27919309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003429. PubMed ID: 16625581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran.
    Zahedi Z; Karimi M; Keshavarz K; Haghpanah S; Ravangard R
    Hematology; 2021 Dec; 26(1):240-248. PubMed ID: 33594948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China.
    Zhou T; Wang S; Zhang Y; Wu R; Li H
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30264. PubMed ID: 36815588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A.
    Colombo GL; Di Matteo S; Mancuso ME; Santagostino E
    Clinicoecon Outcomes Res; 2011; 3():55-61. PubMed ID: 21935333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
    Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.
    Thorat T; Neumann PJ; Chambers JD
    J Manag Care Spec Pharm; 2018 Jul; 24(7):632-642. PubMed ID: 29952709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru.
    Bitrán R; Peña C; Arpón P; Loayza N; Salas K; Del Villar C; Chumpitaz G; Salinas V
    Medwave; 2022 Mar; 22(2):e8703. PubMed ID: 35323824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China.
    Gu C; Huang H; Han Y
    Adv Ther; 2022 Aug; 39(8):3777-3788. PubMed ID: 35768709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
    Kragh N; Tytula A; Pochopien M; Aballéa S; Toumi M; Hakimi Z; Nazir J; Bystrická L; Fatoye F
    Eur J Haematol; 2023 Mar; 110(3):262-270. PubMed ID: 36398467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran.
    Rasekh HR; Imani A; Karimi M; Golestani M
    Clinicoecon Outcomes Res; 2011; 3():207-12. PubMed ID: 22163168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
    Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
    Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.